For some biotechs, AI isn’t just a tool; it’s their entire thesis.
Either way, if you haven’t started experimenting, you’re behind the curve.
But it’s not too late. Chelsea Anderson, Rob Freedman, Matthew Rossiter, Vanessa Park-Thompson, and Ryan Johnson share how life sciences companies are using AI to accelerate drug discovery, diagnostics, healthtech, and more, and how the legal and patent questions are evolving right alongside the science.